Venn Life Sciences – shares restored at a massive premium… but much more to come
Drug development & clinical trial services company Venn Life Sciences (VENN) has announced audited 2018 results, a placing and acquisition (in which Tom Winnifrith has shares) progress which has seen the shares restored to trading – and we have chatted with CEO Cathal Friel…


